Navigation Links
Nation Must Invest in Biomedical Research/Health Workforce, AAHC President Tells Congress
Date:4/10/2012

WASHINGTON, April 10, 2012 /PRNewswire-USNewswire/ -- Prioritized funding for biomedical research and the healthcare workforce is critical to our nation's economy and wellbeing, Dr. Steven A. Wartman, president and CEO of the Association of Academic Health Centers (AAHC), told the House Committee on Appropriations' Subcommittee on Labor, Health and Human Services, Education and Related Agencies in a submitted written statement.  Wartman urged policymakers to "continue to demonstrate bipartisan commitment to a strong economy and improved health" as they deliberate pertinent funding measures.

Wartman presented findings and recommendations to the Subcommittee on the economic impact of biomedical research, noting that "in order to preserve the many benefits of a thriving research community, including American competitiveness abroad, we must continue to invest in the growth of the sector.  Sustained growth of funding for the National Institutes of Health (NIH) is crucial to this endeavor." 

Wartman also argued that access to health care is being threatened by an increasingly inadequate health professions workforce and called on Congress to sufficiently "fund workforce development programs at the Health Resources and Services Administration" and, at a minimum, "maintain the current funding scheme and number of slots for graduate medical education."  He also called for $3 million in appropriations for the National Health Care Workforce Commission, noting the importance of "a comprehensive national strategic vision for health workforce policy and planning" because "the nation's health workforce cannot meet the current needs in underserved areas and the future needs of an aging population."  The Commission is the "right body to develop that vision," according to Wartman.

Recognizing the fiscal pressures of this current environment, Wartman told legislators that "investing in the nation's biomedical research enterprise and in the development of a robust health workforce is critical to ensure a stronger economy and healthier population in the future" adding that the AAHC looks forward to working with Congress to prioritize spending in FY2013 "and into the future."

The AAHC, representing more than 100 academic health centers nationwide, is a national non-profit association dedicated to advancing the nation's health and well-being through the vigorous leadership of academic health centers.   Testimony and information on the workforce is available at: www.aahcdc.org.


'/>"/>
SOURCE Association of Academic Health Centers
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
2. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
3. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
4. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
5. AlphaVax Announces Nomination for 2012 Vaccine Industry Excellence Award
6. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
7. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
8. Dr. Alan Gaby to Present Nutritional Medicine Updates in a Nationwide Tour
9. Groundbreaking National Program to Reverse Obesity Expands to 50 Locations
10. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
11. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a ... from the National Institute of Mental Health (NIMH) for the further advancement of the ... PROZOR technology and is expected to deliver therapeutic levels of olanzapine for a ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... PANAMA CITY , Jan. 26, 2017  Crossmatch, ... today unveiled a new solution aimed at combatting fraud, ... The solution was introduced at the Action on Disaster ... a key meeting point for UN agencies and foreign ... Fraud, waste and abuse are a largely ...
Breaking Biology News(10 mins):